Total Payments
$116,511
2024 Payments
$4,302
Companies
47
Transactions
970
Medicare Patients
15,757
Medicare Billing
$991,866
Payment Breakdown by Category
Other$85,626 (73.5%)
Food & Beverage$17,605 (15.1%)
Research$5,366 (4.6%)
Consulting$4,102 (3.5%)
Travel$3,633 (3.1%)
Education$137.85 (0.1%)
Gifts$40.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $85,590 | 54 | 73.5% |
| Food and Beverage | $17,605 | 875 | 15.1% |
| Unspecified | $5,366 | 2 | 4.6% |
| Consulting Fee | $4,102 | 2 | 3.5% |
| Travel and Lodging | $3,633 | 24 | 3.1% |
| Education | $137.85 | 11 | 0.1% |
| Gift | $40.59 | 1 | 0.0% |
| Entertainment | $35.51 | 1 | 0.0% |
Payments by Type
General
$111,145
968 transactions
Research
$5,366
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| United Therapeutics Corporation | $28,983 | 81 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $20,141 | 107 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $16,234 | 108 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14,457 | 96 | $0 (2023) |
| Gilead Sciences, Inc. | $9,221 | 50 | $0 (2022) |
| Grifols USA, LLC | $7,486 | 20 | $0 (2023) |
| Genentech USA, Inc. | $5,935 | 60 | $0 (2023) |
| GENZYME CORPORATION | $4,469 | 24 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $2,796 | 21 | $0 (2023) |
| GlaxoSmithKline, LLC. | $1,505 | 114 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,302 | 19 | GENZYME CORPORATION ($4,048) |
| 2023 | $2,126 | 96 | AstraZeneca Pharmaceuticals LP ($335.44) |
| 2022 | $2,702 | 145 | AstraZeneca Pharmaceuticals LP ($452.94) |
| 2021 | $1,069 | 50 | Actelion Pharmaceuticals US, Inc. ($310.04) |
| 2020 | $668.04 | 39 | Mylan Specialty L.P. ($93.70) |
| 2019 | $10,410 | 218 | United Therapeutics Corporation ($6,382) |
| 2018 | $14,753 | 187 | United Therapeutics Corporation ($5,601) |
| 2017 | $80,480 | 216 | Actelion Pharmaceuticals US, Inc. ($18,832) |
All Payment Transactions
970 individual payment records from CMS Open Payments — Page 1 of 39
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: Cardiology | ||||||
| 12/04/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $18.99 | General |
| Category: HFCWO | ||||||
| 11/21/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $21.09 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 10/24/2024 | Azurity Pharmaceuticals, Inc. | HORIZANT (Drug) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: CEREBROVASCULARCNS | ||||||
| 10/17/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $19.94 | General |
| Category: HFCWO | ||||||
| 10/14/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: Respiratory | ||||||
| 09/16/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO | Food and Beverage | In-kind items and services | $19.16 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/05/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 09/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $4.95 | General |
| Category: Immunology | ||||||
| 08/05/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 07/11/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $10.92 | General |
| Category: HFCWO | ||||||
| 04/04/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/26/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $15.92 | General |
| Category: HFCWO | ||||||
| 03/07/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $3,672.00 | General |
| Category: Immunology | ||||||
| 03/07/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | Cash or cash equivalent | $132.66 | General |
| Category: Immunology | ||||||
| 03/07/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $115.42 | General |
| Category: Immunology | ||||||
| 01/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: IMMUNOLOGY | ||||||
| 01/16/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $122.60 | General |
| Category: Immunology | ||||||
| 12/06/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $12.59 | General |
| Category: HFCWO | ||||||
| 10/26/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: RESPIRATORY | ||||||
| 10/25/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: Immunology | ||||||
| 10/24/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $76.95 | General |
| Category: Respiratory | ||||||
| 10/11/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $34.69 | General |
| 10/10/2023 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: Anticholinergics, Inhaled | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION PH IN HEART FAILURE WITH PRESERVED EJECTION FRACTION HFPEF | United Therapeutics Corporation | $2,808 | 1 |
| AN OPEN-LABEL EXTENSION STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION PH ASSOCIATED WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION HFPEF - A LONG-TERM FOLLOW-UP TO STUDY TDE-HF-301 | United Therapeutics Corporation | $2,558 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 3,338 | 4,124 | $778,814 | $212,833 |
| 2022 | 21 | 4,172 | 5,161 | $919,926 | $257,308 |
| 2021 | 25 | 3,906 | 5,027 | $882,045 | $263,069 |
| 2020 | 30 | 4,341 | 5,317 | $876,675 | $258,657 |
Total Patients
15,757
Total Services
19,629
Medicare Billing
$991,866
Procedure Codes
101
All Medicare Procedures & Services
101 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 449 | 669 | $162,004 | $56,802 | 35.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 611 | 741 | $122,447 | $44,362 | 36.2% |
| 94375 | Test to measure rate of airflow | Office | 2023 | 731 | 1,069 | $123,779 | $27,968 | 22.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 169 | 169 | $61,468 | $19,502 | 31.7% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 28 | 28 | $55,543 | $11,965 | 21.5% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 247 | 269 | $44,137 | $10,534 | 23.9% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 306 | 344 | $32,008 | $8,056 | 25.2% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 190 | 190 | $29,228 | $7,480 | 25.6% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 13 | 13 | $27,885 | $6,163 | 22.1% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 226 | 248 | $51,948 | $5,783 | 11.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 69 | 69 | $16,338 | $5,381 | 32.9% |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 2023 | 48 | 48 | $21,140 | $2,497 | 11.8% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2023 | 14 | 14 | $8,372 | $1,281 | 15.3% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2023 | 12 | 12 | $9,904 | $1,137 | 11.5% |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | Office | 2023 | 40 | 41 | $4,633 | $1,121 | 24.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 27 | 27 | $2,673 | $1,103 | 41.3% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2023 | 63 | 67 | $3,685 | $901.69 | 24.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 72 | 83 | $581.00 | $563.56 | 97.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 12 | $696.00 | $129.00 | 18.5% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 11 | 11 | $344.85 | $105.50 | 30.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 845 | 1,087 | $179,355 | $65,963 | 36.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 365 | 553 | $132,720 | $50,268 | 37.9% |
| 94375 | Test to measure rate of airflow | Office | 2022 | 818 | 1,248 | $133,080 | $33,539 | 25.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 233 | 233 | $84,812 | $28,048 | 33.1% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 325 | 354 | $56,640 | $14,770 | 26.1% |
About Dr. Carlton Cauthen, M.D
Dr. Carlton Cauthen, M.D is a Pulmonary Disease healthcare provider based in Columbia, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346258746.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carlton Cauthen, M.D has received a total of $116,511 in payments from pharmaceutical and medical device companies, with $4,302 received in 2024. These payments were reported across 970 transactions from 47 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($85,590).
As a Medicare-enrolled provider, Cauthen has provided services to 15,757 Medicare beneficiaries, totaling 19,629 services with total Medicare billing of $991,866. Data is available for 4 years (2020–2023), covering 101 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Pulmonary Disease, Critical Care Medicine
- Location Columbia, SC
- Active Since 08/03/2006
- Last Updated 06/24/2022
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1346258746
Products in Payments
- ORENITRAM (Drug) $18,616
- BEVESPI AEROSPHERE (Drug) $14,363
- UPTRAVI (Drug) $14,076
- Prolastin-C (Biological) $7,283
- Letairis (Drug) $6,352
- OPSUMIT MACITENTAN (Drug) $5,594
- Esbriet (Biological) $5,420
- DUPIXENT (Biological) $5,012
- Adempas (Drug) $2,796
- Arikayce (Drug) $746.40
- TRELEGY ELLIPTA (Drug) $701.72
- NONE (Drug) $660.00
- OFEV (Drug) $548.20
- SYMBICORT (Drug) $543.77
- Xolair (Biological) $483.68
- STIOLTO RESPIMAT (Drug) $418.49
- SMARTVEST (Device) $418.19
- OPSUMIT (Drug) $406.28
- FASENRA (Drug) $355.32
- NUCALA (Biological) $339.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Columbia
Dr. Richard Bogan, M.d, M.D
Pulmonary Disease — Payments: $1.2M
Pulmonary Disease $1.2M
Dr. Laura Herpel, M.d, M.D
Pulmonary Disease — Payments: $144,324
Pulmonary Disease $144,324
Mr. Mark Mayson, Md, MD
Pulmonary Disease — Payments: $49,937
Pulmonary Disease $49,937
Edward Schaefer, Md, MD
Pulmonary Disease — Payments: $16,280
Pulmonary Disease $16,280
Jason Goodin, D.o, D.O
Pulmonary Disease — Payments: $14,722
Pulmonary Disease $14,722
Yuji Oba, M.d, M.D
Pulmonary Disease — Payments: $14,418
Pulmonary Disease $14,418